Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer

  • Authors:
    • Hidemi Kawajiri
    • Tsutomu Takashima
    • Naoyoshi Onoda
    • Shinichiro Kashiwagi
    • Satoru Noda
    • Tetsurou Ishikawa
    • Kenichi Wakasa
    • Kosei Hirakawa
  • View Affiliations

  • Published online on: July 13, 2012     https://doi.org/10.3892/ol.2012.801
  • Pages: 612-616
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sequential administration of anthracyclin and taxane for neoadjuvant chemotherapy (NAC) is the standard treatment for operable breast cancer. The pathological complete response (pCR) is a significant predictor of overall survival (OS), regardless of treatment. In this study, the pCR rate was retrospectively examined and compared with the treatment efficacy and the characteristics of pCR patients were analyzed. A total of 54 female patients with operable breast cancer, treated with FEC 100 followed by weekly paclitaxel between December 2005 and May 2009 at the Osaka City University Hospital, Osaka, Japan, were retrospectively reviewed. A total of 21 patients (39%) achieved pCR. The overall response rate was 91%. Only one patient had progressive disease. The pCR rate was significantly higher in those patients with estrogen receptor (ER)- and progesterone receptor (PR)-negative tumors and in those patients who completed the treatment course. An NAC regimen incorporating FEC 100 followed by weekly paclitaxel is effective for treating operable breast cancer.
View Figures
View References

Related Articles

Journal Cover

October 2012
Volume 4 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kawajiri H, Takashima T, Onoda N, Kashiwagi S, Noda S, Ishikawa T, Wakasa K and Hirakawa K: Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer. Oncol Lett 4: 612-616, 2012
APA
Kawajiri, H., Takashima, T., Onoda, N., Kashiwagi, S., Noda, S., Ishikawa, T. ... Hirakawa, K. (2012). Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer. Oncology Letters, 4, 612-616. https://doi.org/10.3892/ol.2012.801
MLA
Kawajiri, H., Takashima, T., Onoda, N., Kashiwagi, S., Noda, S., Ishikawa, T., Wakasa, K., Hirakawa, K."Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer". Oncology Letters 4.4 (2012): 612-616.
Chicago
Kawajiri, H., Takashima, T., Onoda, N., Kashiwagi, S., Noda, S., Ishikawa, T., Wakasa, K., Hirakawa, K."Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer". Oncology Letters 4, no. 4 (2012): 612-616. https://doi.org/10.3892/ol.2012.801